The low probability of developing teratomas, high homing potential, the production of neuroprotective cytokines such as amphiregulin, macrophage inflammatory protein-3 beta (MIP-3b), fibroblasts growth factor-6 (FGF-6), glucocorticoid-induced tumor necrosis factor receptor family-related gene (GITR), interleukin 10 (IL-10), osteoprotegerin, and neurotrophins like brain-derived neurotrophic factor (BDNF), along with their immunomodulatory and anti-inflammatory properties, make MSCs good candidates for cell therapy [51,52]. This evidence concerns the gene CCL19 and teratoma.